US 12,444,507 B2
Bayesian causal inference models for healthcare treatment using real world patient data
Bin Huang, Cincinnati, OH (US)
Assigned to Children's Hospital Medical Center, Cincinnati, OH (US)
Appl. No. 17/310,176
Filed by Children's Hospital Medical Center, Cincinnati, OH (US)
PCT Filed Jan. 24, 2020, PCT No. PCT/US2020/014912
§ 371(c)(1), (2) Date Jul. 23, 2021,
PCT Pub. No. WO2020/154573, PCT Pub. Date Jul. 30, 2020.
Claims priority of provisional application 62/959,530, filed on Jan. 10, 2020.
Claims priority of provisional application 62/952,872, filed on Dec. 23, 2019.
Claims priority of provisional application 62/952,935, filed on Dec. 23, 2019.
Claims priority of provisional application 62/796,636, filed on Jan. 25, 2019.
Prior Publication US 2022/0093271 A1, Mar. 24, 2022
Int. Cl. G16H 50/70 (2018.01); G06N 7/01 (2023.01); G16H 10/60 (2018.01); G16H 50/20 (2018.01)
CPC G16H 50/70 (2018.01) [G06N 7/01 (2023.01); G16H 10/60 (2018.01); G16H 50/20 (2018.01)] 12 Claims
OG exemplary drawing
 
1. A method for treating juvenile idiopathic arthritis (JIA) in a subject in need thereof, the method comprising
implementing a Bayesian nonparametric causal inference method for determining the more effective treatment among two alternative JIA treatments administered to a plurality of JIA patients by a non-transitory machine readable storage medium storing at least one program that when executed by at least one processor, causes the at least one processor to implement the Bayesian nonparametric causal inference method, the method comprising generating a marginal structural model and performing a single step of Bayesian regression on patient data of the plurality of patients, wherein the method incorporates matching, weighting, and estimation processes into the single regression step and wherein the matching process is performed using a Gaussian process (“GP”) prior covariance function; and
administering to the subject the JIA treatment determined by the Bayesian nonparametric causal inference method to be more effective, wherein the JIA treatment is either a combination of biologic disease modifying antirheumatic drugs (bDMARDs) and conventional synthetic disease modifying antirheumatic drugs (csDMARDs) or csDMARDs alone, without administration of bDMARDs, wherein the csDMARDs comprise methotrexate and the bDMARDs comprise adalimumab or etanercept.